Understanding Tennis Elbow: It’s Not Just for Athletes

Tennis elbow, medically known as Lateral Epicondylitis, is a common overuse injury affecting the outer part of the elbow. Despite its name, most patients with tennis elbow are not professional athletes. It frequently occurs in people who perform repetitive wrist and arm movements, such as office workers, mechanics, golfers, gym enthusiasts, and individuals who use a computer mouse extensively.

The condition involves degeneration of the extensor tendons, particularly the extensor carpi radialis brevis (ECRB) tendon, where it attaches to the lateral epicondyle of the humerus. Rather than being a purely inflammatory disorder, modern research shows that tennis elbow is more accurately described as a degenerative tendinopathy. The tendon fibers undergo microscopic tearing, collagen disorganization, and reduced healing capacity over time.

Why Does Tennis Elbow Become Chronic?

In early stages, patients may experience mild pain when gripping objects, lifting items, or shaking hands. However, when repetitive strain continues without adequate recovery, the tendon’s microtears accumulate faster than the body can repair them.

Unlike muscles, tendons have relatively poor blood supply. This limited vascularity slows healing and makes chronic tendinopathy more likely. Over time, the tendon structure becomes weaker and less organized, leading to persistent pain and reduced grip strength.

Importantly, chronic tennis elbow is not primarily driven by acute inflammation. This explains why anti-inflammatory medications or steroid injections may provide temporary symptom relief but do not necessarily restore tendon structure.

Standard Treatment Approaches

Conventional management usually includes activity modification, physiotherapy, bracing, and nonsteroidal anti-inflammatory drugs. In some cases, corticosteroid injections are used for short-term pain control. Platelet-rich plasma (PRP) has also been used in an attempt to stimulate biological healing.

Surgery is reserved for severe, refractory cases that fail conservative treatment for six to twelve months.

However, many patients fall into a “gray zone” — persistent pain, structural degeneration visible on imaging, but not severe enough for surgery. This is where regenerative approaches are increasingly discussed.

How Stem Cell Therapy May Play a Role

Mesenchymal stem cells (MSCs), particularly those derived from umbilical cord tissue (UC-MSCs), are studied in regenerative medicine because of their ability to modulate inflammation and support tissue repair.

It is important to clarify that stem cells do not simply “replace” damaged tendon tissue. Their primary mechanism is paracrine signaling. They release growth factors, cytokines, and extracellular vesicles that influence the local healing environment.

In chronic tendinopathy such as tennis elbow, stem cells may potentially:

• Support collagen remodeling by promoting more organized tendon fiber regeneration.
• Reduce chronic inflammatory signaling that perpetuates tendon degeneration.
• Enhance angiogenesis, improving microcirculation in poorly vascularized tendon tissue.
• Stimulate tenocyte activity, supporting structural repair over time.

What the Evidence Says

Clinical data on stem cell therapy specifically for lateral epicondylitis remains limited but evolving. Most evidence comes from broader research on tendinopathy and orthopedic regenerative applications. Early studies suggest potential benefits in pain reduction and functional improvement, particularly in chronic cases resistant to conservative therapy.

However, large-scale randomized trials are still needed. Stem cell therapy for tennis elbow is considered an advanced regenerative option rather than standard first-line treatment.

Who May Be a Candidate?

Stem cell therapy may be considered in patients who have chronic lateral epicondylitis lasting several months despite structured physiotherapy and conservative care. It may also be discussed in individuals seeking to avoid surgical intervention.

It is not appropriate for acute minor strains that are likely to recover with rest and rehabilitation. Proper diagnosis through physical examination and imaging is essential before considering any regenerative intervention.

Setting Realistic Expectations

Stem cell therapy does not provide instant pain relief like corticosteroid injections. The goal is structural improvement and biological repair, which may take weeks to months. Outcomes vary depending on age, severity of degeneration, biomechanical factors, and adherence to post-procedure rehabilitation.

Tennis elbow is fundamentally a load-management problem. Without correcting repetitive strain and improving biomechanics, no regenerative therapy will provide durable benefit.

Tennis elbow is a degenerative tendon condition caused by repetitive stress and impaired healing. While many cases resolve with conservative care, chronic cases may benefit from regenerative approaches aimed at improving tendon biology rather than suppressing symptoms.

Stem cell therapy represents a developing option within orthopedic regenerative medicine. It should be considered selectively, under medical supervision, and with clear understanding of both its potential and its limitations.

About EDNA Wellness

EDNA Wellness is a private Stem Cell Clinic and Regenerative Medicine Center in Bangkok, Thailand, specializing in Umbilical cord–derived Mesenchymal Stem Cells (UC-MSCs) for knee osteoarthritis and joint pain, stroke and other neuro-related conditions, and stem cell IV infusions for longevity and healthy aging. All treatments are doctor-designed and performed in a sterile clinical setting

For more information or to book a consultation:

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

Website: www.ednawellness.com

References

• Coombes BK, Bisset L, Vicenzino B. Effect of corticosteroid injection, physiotherapy, or both on clinical outcomes in lateral epicondylalgia. JAMA. 2013.
  https://pubmed.ncbi.nlm.nih.gov/23385272/
• Lui PPY. Stem cell technology for tendon regeneration: current status and future research directions. Stem Cells and Cloning. 2015. https://pubmed.ncbi.nlm.nih.gov/26715856/
• Andia I, Maffulli N. New biotechnologies for musculoskeletal injuries. Surgeon. 2019. https://pubmed.ncbi.nlm.nih.gov/30170915/